Technology Assessment Reports (TARs)
PHARMAC's Hospital Pharmaceutical Assessment Final Summary Discussion Document No.6 Celecoxib (Celebrex) and rofecoxib (Vioxx) - selective COX-2 inhibitors - for osteoarthritis and rheumatoid arthritis (20 pages, 338 KB) - February 2004. See also media release
PHARMAC's analysis of combined long-acting beta agonist/inhaled corticosteroid devices for asthma (18 pages, 75 KB) and referred to in letter to Journal of Allergy & Clinical Immunology (Metcalfe, Moodie 2003)
Updated statin cost utility analysis 2002 (Technology Assessment Report No. 19) (11 pages, 119 KB) - includes supporting appendices (previous cost utility anayses for statins detailing methods, etc):
- 1997 statin cost utility analysis (Technology Assessment Report No. 1) - methods and assumptions (59 pages, 630 KB)
- 1997 statin cost utility analysis (Technology Assessment Report No. 1) - summary of results (10 pages, 244 KB)
- 1997 statins for familial hyperlipidaemia (Technology Assessment Report No. 2). (15 pages, 237 KB)
Celebrex's relative GI safety is overstated? (9 pages, 1176 KB) - a critique and reworking of an industry-sponsored meta-analysis of COX-2 inhibitors (Deeks et al 2002), sent as a letter to the British Medical Journal, October 2002.
- Supporting data for this analysis is available in a zipped Excel spreadsheet file.
-
Further commentary,
I and II from the British Medical Journal Website
-
The original paper from the British Medical Journal's website.
Page updated on 16 Apr 2008
Linked documents
Hospital Pharmaceutical Assessment Final Summary Discussion Document No 6 (20 pages, 338 KB)
Celecoxib (Celebrex) and rofecoxib (Vioxx) - selective COX-2 inhibitors - for osteoarthritis and rheumatoid arthritis.
Effectiveness of combined ICS/LABAs (18 pages, 75 KB)
Effectiveness of combined ICS/LABAs delivery devices versus concurrent ICS and LABA via separate inhalers.
Statins Cost Utility Analysis (11 pages, 119 KB)
Updated cost utility analysis for statins Scott Metcalfe Pharmac 30 January 2001 Pharmac estimates the cost-utility of providing statins to everyone with dyslipidaemia and > 10% 5-year absolute risk of cardiovascular events, at a proposed price of $0.45/day, is $1,630/QALY…
1997 Statin Cost Utility Analysis (Technology Assessment Report No. 1) (59 pages, 630 KB)
This paper describes a model which PHARMAC has developed to assess the costs and benefits of extending subsidy criteria for lipid-modifying agents (LMAs). The model assesses both need for and cost-effectiveness/benefits of these agents. Impact is in terms of costs and benefits, from two perspectives: 1. a financial perspective (costs and savings for pharmaceuticals), and 2. a health economic perspective (pharmaceuticals, plus other impact on health sector costs, mortality and quality of life).
Summary – Cost utility analysis of the lipid modifying agents (10 pages, 244 KB)
1997 Summary – cost utility analysis of the lipid modifying agents. The benefits of LMAs can be measured in quality-adjusted life years saved (QALYS), which combine fatal with non-fatal events.
1997 Statins for Familial Hyperlipidaemia (Technology Assessment Report No. 2) (15 pages, 237 KB)
This paper examines the incremental benefits and costs of treating patients with familial hyperlipidaemia with simvastatin 40mg/day, over and above the net costs and benefits of treatment with fluvastatin 80mg/day. The analysis assumes that for familial hyperlipidaemia that benefit is proportional to the degree of LDL-cholesterol lowering, given the lack of evidence for this condition.
Letter to British Medical Journal: Is Celebrex's relative GI safety overstated? (9 pages, 1176 KB)
Is Celebrex’s relative GI safety is overstated? The editorial by Roger Jones makes important points about the limitations of the meta-analysis by Jon Deeks and colleagues2 for celecoxib. However, we also note that the Deeks meta -analysis does not account for the 12-15-month data for the CLASS study compiled by the FDA3 4 and cited by Peter Juni and colleagues’ critical editorial.
